'Pharmaceutical Licensing Strategies' Provides a Detailed Analysis of Licensing Strategies in the Pharmaceutical and Biotechnology Industries.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43236) has announced the addition of Pharmaceutical Licensing Strategies: Best Practices in Deal-Making, Valuations and Strategic Management to their offering. With falling R&D productivity and continued healthcare cost containment cost containment, n the features of a dental benefits program or of the administration of the program designed to reduce or eliminate certain charges to the plan. and generic competition pushing down the returns available for successfully launched products, only those companies able to complement internal efforts with a strong partnering strategy will be able to remain competitive over the next five-to-ten years. Pharmaceutical licensing strategies: Best practices in deal-making, valuations and strategic management provides a detailed analysis of licensing strategies in the pharmaceutical and biotechnology industries. The report draws upon deal-making trend data, primary research survey results and a profile of best practices in pharmaceutical licensing in order to present a set of actionable Giving sufficient legal grounds for a lawsuit; giving rise to a Cause of Action. An act, event, or occurrence is said to be actionable when there are legal grounds for basing a lawsuit on it. recommendations for optimizing deal-making. About the Author: Steven Seget is Principal at Delphi Pharma, and provides independent strategic consulting services Noun 1. consulting service - service provided by a professional advisor (e.g., a lawyer or doctor or CPA etc.) service - work done by one person or group that benefits another; "budget separately for goods and services" to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and has an MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration from the London Business School Around 800 degree students, from 70 countries, graduate from the school each year. Over 80 percent of students, and over 70 percent of faculty, come from outside the UK. A further 6,000 executives attend the school executive education programmes each year. . The Chapter outline is below: Executive Summary Introducing pharmaceutical licensing Licensing trends Licensing process Licensing valuations Licensing best practices Chapter 1 Introducing pharmaceutical licensing Chapter 2 Licensing trends Chapter 3 Licensing process Chapter 4 Licensing valuations Chapter 5 Licensing best practices Chapter 6 Appendix List of Figures List of Tables Companies Mentioned Include: -- Genentech-Roche -- Idenix-Novartis -- Millennium-Ortho Biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. -- AstraZeneca-AtheroGenics -- Novartis -- Cephalon Ceph´a`lon n. 1. (Zool.) The head. For more information visit http://www.researchandmarkets.com/reports/c43236 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion